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Review 
  
Abstract 
Bone disease in the neonatal period has often been regarded as an issue affecting 
premature infants, or a collection of rare and ultra-rare disorders that most 
neonatologists will see only once or twice each year, or possibly each decade. 
The emergence of targeted therapies for some of these rare disorders means that 
neonatologists may be faced with diagnostic dilemmas that need a rapid solution 
in order to access management options that did not previously exist.   
The diagnostic modalities available to the neonatologist have not changed a 
great deal in recent years; blood tests and radiographs still form the mainstays 
with other techniques usually reserved for research studies, but rapid access to 
genomic testing is emergent. This paper provides an update around diagnosis 
and management of bone problems likely to present to the neonatologist. 
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Metabolic bone disease of prematurity  
At birth, the transplacental supply of calcium and phosphate that has provided 
the mineral substrates for both hard tissue mineralisation and soft tissue growth 
ceases. Calcium falls rapidly, reaching a nadir around 24-48 hours of age,1 
provoking PTH production2 with the physiological consequences listed below.  In 
very sick infants, the fall in blood calcium levels can be greater and last for 
longer; maternal antenatal vitamin D deficiency may also be a factor in this 
situation.3 
Renal phosphate excretion increases and fasting serum phosphate levels fall 
when PTH rises. Phosphate is required for the apoptosis of hypertrophic 
chondrocytes in the growth plate, as well as mineralisation of newly formed 
bone matrix.4 Lack of phosphate leads both to persistence of hypertrophic 
chondrocytes and reduced ossification in the primary spongiosa, the new bone 
initially formed at the growth plate. Phosphate levels typically decline over the 
first two weeks of life but are hard to assess accurately due to the difficulty in 
obtaining fasting samples in orally-fed infants; non-fasting levels reflect recent 
phosphate intake. 
 
The diagnosis of metabolic bone disease of prematurity, also known as 
osteopenia of prematurity, osteopathy of prematurity and preterm rickets, is 
often made on the basis of raised serum alkaline phosphatase.  Alkaline 
phosphatase is present on the surface of bone-forming cells, osteoblasts, and on 
osteoblast-derived matrix vesicles found in areas of active new bone formation 
and mineralisation.5 The role of alkaline phosphatase here is to remove the 
mineralisation inhibitor pyrophosphate (PPi) in order that newly formed 
mineral crystals that grow within and then rupture from matrix vesicles can seed 
into the calcium and phosphate-containing fluid that bathes the bone surface,5 
with further propagation of tissue mineralisation following. The level of alkaline 
phosphatase in the prematurely born infant may thus reflect the rate at which 
mineral crystals form, grow and disrupt the matrix vesicles releasing alkaline 
phosphatase into the circulation. 
 
Rickets is characterised by the failure to mineralise newly formed bone. Alkaline 
phosphatase increases in every rachitic disorder with the exception of 
hypophosphatasia (see later). Thus in every rachitic disorder, the rate of mineral 
crystal release from matrix vesicles is increased, but without consequent 
increase in tissue mineralisation. Either the crystals are being destroyed, or 
there is insufficient mineral substrate available for the further propagation of 
bone matrix mineralisation.  
 
In nutritional rickets in older children, lack of vitamin D results in reduced 
absorption of calcium from the gut. In response to falling serum calcium levels, 
parathyroid hormone (PTH) excretion increases and acts on osteoblasts to 
increase secretion of RANK-ligand, an activator of the cells that resorb bone, the 
osteoclasts.6 Both calcium and phosphate are released from bone, with 
restoration of circulating calcium and avoidance of the neuromuscular 
consequences of hypocalcemia. PTH acts on the kidney to increase calcium 
resorption and also increases the conversion of 25-hydroxyvitamin D (the ǲǳȌ
to the active metabolite 1,25dihyroxyvitamin D that both increases 
gastrointestinal calcium (and probably phosphate) uptake and acts coordinately 
with RANK-ligand to promote osteoclastic activity. PTH also increases renal 
phosphate excretion, and PTH production is increased in response to prolonged 
phosphate exposure. 
 
As serum phosphate falls after delivery, so the hypertrophic chondrocyte cell 
layer increases in depth, resulting in growth plate widening. This is difficult to 
see on plain radiographs in preterm infants, because secondary ossification 
centres only appear on distal femur radiographs ex utero at around 36 weeks 
gestation in some series7 and later at other epiphyses. Other imaging modalities 
have not been employed to assess growth plate widening, although ultrasound 
has been used to assess the appearance of secondary ossification centres.  
Ossification centres in the distal femurs are reliably detected by prenatal 
ultrasound at 33 weeks8. 
 
Alkaline phosphatase (ALP) values are assay-specific and thus may vary 
considerably between centres. ALP typically rises in the three weeks following 
delivery before plateauing at a level approximately two to three times the 
maximum of the adult normal range.9 ALP in combination with serum phosphate 
at two weeks age has been found to be predictive of later bone mineral density 
by dual energy x-ray absorptiometry(DXA)10. Others have found that PTH 
>180ng/l  and phosphate <4.6mg/dl (<1.4mmol/l) at age 3 weeks, rather than 
raised ALP, was predictive of metabolic bone disease as shown by altered distal 
femoral appearance on plain radiographs at age 6 weeks.11 
 
Bone mineralisation will be affected when substrate supply - i.e. calcium and 
phosphate - is reduced. The accumulation of mineralised bone mass may be 
influenced by other factors. In older individuals, both immobility and 
inflammation have been clearly demonstrated to adversely affect bone accrual. 
Sick preterm infants are often relatively immobile, and are subject to a range of 
inflammatory insults such as infection and necrotising enterocolitis. These 
factors in combination result in lower mineralised bone mass that in turn 
predisposes to fracture. Identifying and mitigating these risks before fracture 
occurs is clearly desirable.  
 
Measurement of mineralised bone mass by DXA requires transportation to the 
scanner; values are not comparable between the different manufacturers. The 
commonly reported value of areal bone mineral density of the lumbar spine 
(LSaBMD) reflects bone size as well as mass; bone mineral apparent density 
(BMAD) is a calculated estimate of lumbar spine volumetric density based on an 
assumed cubic vertebral shape and is less affected by bone size.12 Tibial 
ultrasound has been used to measure speed of sound (SoS) ǲǳ13; it is unclear what precisely is being measured, although studies in 
adults show a relationship of SoS with tibial cortical thickness. Neither measure 
appears to be discriminatory in identifying those at risk of fracture, and hence 
have not entered routine clinical practice. 
 
Starting in the 1980s, the management of metabolic bone disease of prematurity 
focused on providing an increased amount of mineral substrate.  The basis of this 
intervention is supported through a multitude of interventional supplementation 
studies, although the optimal level of supplementation for any given infant 
remains the subject of debate. It is clear, however, that no additional benefit 
accrues through the use of more than 400IU (10mcg) vitamin D daily.14,15  
Physicochemical constraints in respect of the solubility of inorganic calcium and 
phosphate salts in intravenous feeding solutions resulted in efforts to either 
supply additional oral supplements or avoid solubility issues through the use of 
organic phosphate salts.16 Most multi-nutrient fortifiers for breast milk and 
preterm infant formulas contain large amounts of both calcium and phosphate. 
In some instances, additional phosphate alone is given, typically in doses of 1.0 -
1.5 mmol/kg/day. Phosphate can complex with calcium in the gut, so ideally 
additional phosphate should be given separately to the feeds, clearly an 
unrealistic proposition in those receiving continuous or hourly bolus feeds. 
Phosphate can be admixed with expressed breast milk; it is thought to enter the 
micelles, so if additional calcium is also to be administered, add the phosphate 
first, mix gently and leave for 30 minutes before adding the calcium. 
 
Additional calcium may be required for some infants, typically those born very 
preterm, as they grow and develop. The key indicator here is PTH; if serum 
calcium is normal but PTH is raised, this suggests inadequate calcium supply. 
Further vitamin D supplementation, or the use of active vitamin D metabolites, 
will not help; additional calcium, and reducing additional phosphate intake, will. 
 	ǲǳǢ
often in infants born weighing <1000g, who have chronic lung disease 
(presumably a marker for inflammation and immobility, as well as allowing 
more frequent radiological assessment), prolonged intravenous feeding/delayed 
enteral feeds, conjugated hyperbilirubinaemia, steroids and diuretics, and 
physiotherapy.17  It is appropriate to give advice to both parents and staff 
regarding the increased risk of fractures and need for careful handling to try and 
reduce fracture risk both in hospital and after discharge home. 
 
Osteogenesis imperfecta/inherited bone fragility 
The last two decades has been transformative in terms of our understanding of 
the genetic origins of bone fragility (although this remains incomplete), less so in 
terms of therapeutic interventions Ȃ until recently.  
Osteogenesis imperfecta (OI) has been used as an umbrella term for inherited 
bone fragility conditions; over time, there has been a growing acceptance that ǲǳ
identify and differentiate OI from bone fragility as the dominant material 
property of OI bone is its brittleness, likely a combination of increased amounts 
of mineral platelets in relation to the proteinaceous matrix, with additional 
stiffening of the matrix through excessive non-enzymatic cross-linking.18  
The genetic origins of inherited bone fragility are listed in Table 1.  The list is 
ever-expanding but useful in terms of providing advice to families as inheritance 
patterns vary, although dominant inheritance remains the most common. Many 
of the genes are involved in the production, processing or export of type I 
collagen from osteoblasts, the bone-forming cells. There are no specific 
treatments for any of the different forms as yet, although one might anticipate 
that an enterprising biotech company will eventually produce the replacement 
protein for type VI. ǲǳǡ
identified on antenatal scans. At birth, bones look lucent as well as short and may 
be bowed or fractured. Characteristic features that can help distinguish type V OI 
at birth are metaphyseal changes suggesting rickets or dysplasia,19 and a wedge-
shaped inclusion in the anterior wall of the vertebrae seen on lateral spine 
radiographs. Infants with fragile bones and contractures may have Bruck 
Syndrome,20-22 resulting from defects in FKBP10 or PLOD2; those with 
craniosynostosis may have Cole-Carpenter syndrome, caused by defects in P4HB 
or SEC24D.23-25 In those where there are concerns about neurodevelopment, 
Wnt1 mutations should be considered.26,27 
 
Insert Table 1 here: 
 
Table 1. Inherited bone fragility syndromes 
 
 
Gene Sillence 
type/ 
syndrome 
name 
Severity Protein Additional phenotypic 
details 
Collagen molecule 
COL1A1 I-IV Mild-
lethal  
 
 ?Ƚ ?
chain 
High bone mass in C-
propeptide cleavage site 
defects Ȃ ǲǳ
bones28  
Caffey disease with defect at 
p.Arg1014Cys29  
COL1A2 I-IV Mild-
lethal  
 
 ?Ƚ ?
chain 
High bone mass in C-
propeptide cleavage site 
defects  
Collagen folding 
CRTAP III Severe-
lethal  
Cartilage associated 
protein 
Cole-Carpenter features 
reported in one case.30 
LEPRE1 III Severe-
lethal  
Prolyl-3-hydroxylase  
PPIB III Moderate
-lethal  
Cyclophilin B  
Collagen stability 
FKBP10 III Moderate
-severe  
FKBP65; 65kD 
FK506-binding 
protein 
Bruck syndrome (OI with 
contractures)20,22; 
Kuskokwim syndrome 
(contractures alone)31  
PLOD2 Bruck 
syndrome 
Moderate
-severe  
Lysyl hydroxylase 2 Contractures  
SERPINH1 III Severe  Heat Shock Protein 47 Pyloric stenosis, skin bullae, 
renal stones32  
SPARC III Moderate
-severe  
Secreted protein, 
acidic, cysteine-rich; 
osteonectin 
Notable sarcopenia33  
 
Collagen processing/cleavage 
BMP1 III Mild-
moderate 
Bone morphogenetic 
protein 1; tolloid 
High bone mass, similar to 
C-propeptide cleavage 
defects, hyperosteoidosis, 
cardiac defects34-37 
Wnt-signalling pathway 
WNT1 III Mild-
severe 
Wingless-type MMTV 
integration site 
family, member 1 
Homozygous Ȃ severe OI; 
some have brain 
malformation; autism, 
learning difficulties in 
some.26,27 
Heterozygous Ȃ early onset 
osteoporosis, normal 
growth  
Mineralisation regulation 
IFITM5/  
BRIL 
V Moderate
- severe  
Interferon-induced 
transmembrane 
protein 5, or, bone-
restricted IFITM5-
like 
Metaphyseal dysplasia and 
sclerosis, hypertrophic 
callus, interosseous 
membrane calcification. 38-
41 
SERPINF1 III Moderate
-severe 
Pigment epithelium 
derived factor 
Slowly progressively 
worsening OI; osteoid 
mineralization defect (no 
endochondral defect)42 
Osteoblast lineage 
SP7/OSX III Severe Specificity Protein 7; 
Osterix 
Typical OI features43  
 
Developmental/patterning 
TAPT1 III Lethal Transmembrane 
anterior posterior 
transformation-1 
protein 
Complex 
osteochondrodysplasia with 
multiple fractures; also 
have brain, 
cardiorespiratory and renal 
defects 44 
ER-related 
P4HB III Moderate
-severe 
Prolyl 4-
hydroxylase; protein 
disulfide isomerase 
Cole-Carpenter syndrome; 
craniosynostosis, ocular 
proptosis, 
hydrocephalus23,25,45 
TMEM38B III Moderate
-severe 
Trimeric 
Intracellular Cation 
Channel Type B; 
TRIC-B 
Severe osteopenia and limb 
fractures without vertebral 
fractures 46,47 
CREB3L1 III Severe Old Astrocyte Severe OI; cardiac failure 48 
Specifically Induced 
Substrate - OASIS 
SEC24D III Moderate
-severe 
Component of COPII 
complex 
Cole-Carpenter syndrome; 
craniosynostosis, ocular 
proptosis, hydrocephalus24  
MBTPS2  
 
III Moderate
-severe 
Site-2 
metalloproteinase 
S2P 
regulated intramembrane 
proteolysis of transcription 
factors such as OASIS  
x-linked49  
Nucleotidyltransferase fold protein 
FAM46A III Severe Family with 
sequence similarity 
46A 
Stüve-Wiedemann Ȃ like 
features, blue sclerae50  
Linker enzyme deficiency 
XYLT2 III Moderate
-severe 
Xylosyltransferase II Vertebral fractures, 
cataracts, heart defects 51 
Bone fragility, not clearly OI 
LRP5/6 N/A Mild-
severe 
Lipoprotein 
receptor-related 
protein 5/6 
Homozygous Ȃ osteoporosis 
pseudoglioma syndrome; 
Heterozygous Ȃ 
osteoporosis and/or 
vitreoretinopathy 52-55 
NBAS N/A Moderate
-severe 
Neuroblastoma 
Amplified Sequence 
Early onset osteoporosis, 
recurrent acute liver failure, 
developmental delay56,57  
LIFR Stüve-
Wiedemann 
syndrome 
Moderate
-severe 
Leukaemia 
inhibitory factor 
receptor 
 
Long bone bowing, 
camptodactyly, 
hyperpyrexia, fractures 
later58 
Osteocyte dysfunction 
PLS3 N/A N/A Plastin 3 X-linked early onset severe 
osteoporosis without other 
OI features59,60 
 
 
Next generation sequencing (NGS) allows high performance sequencing of whole 
genomes or can be limited to a smaller number of genes of interest.  The original 
Sangar method of sequencing DNA was a time consuming and expensive process 
sequencing one DNA fragment at a time.  NGS allows the parallel sequencing of 
millions of DNA fragments simultaneously.  These can then be compared to large 
online databases cataloguing genetic variability to identify a causative gene.  It 
may also be possible to identify a causative gene through comparison of a very 
small number of individuals but this may also identify non-causative variants.  
NGS can be performed at relatively low cost (around £200/sample); specific 
panels are available for bone fragility and skeletal dysplasia that allow the ǲǳǢǲǳ 
candidate mutations, but may still fail to identify mutations that lie outside of 
coding or regulatory regions.   
Management, as with most skeletal disorders, is multidisciplinary.61  Whilst the ǯǡ
the on-going management of the musculoskeletal system requires 
physiotherapy, occupational therapy and nursing involvement from the outset, 
especially in respect of moving and handling, and input from a psychologist and 
social worker in due course.  Bisphosphonates are given intravenously in this age 
group; in the UK, this is usually pamidronate, but zoledronic acid has been given 
in some North American centres. Indications for starting bisphosphonates in 
infants with OI are the presence of multiple fractures, and the need for pain 
relief; bisphosphonates are widely reported by older children to reduce 
musculoskeletal pain and improve endurance and fatigue. 
New treatments are emerging. Denosumab, an anti-RANK-ligand antibody 
licenced for the treatment of post-menopausal osteoporosis,62 has been used in 
some children with type VI OI63 and is currently being trialled in a phase 3 study 
of older children with commoner forms of OI. RANK-ligand is the principal factor 
that both attracts and activates mononuclear cells to fuse to become osteoclasts, 
and then promotes their activity in resorbing bone. 
Anti-sclerostin antibody treatment is being evaluated in adults with OI,64 and 
will start paediatric trials in 2019. Sclerostin, produced by osteocytes, both 
inhibits bone formation and increases bone resorption.65 Anti-sclerostin 
antibody thus increases bone mass, and does so on both modelling (addition or 
removal of bone without prior resorption) and remodelling (removal of bone 
with replacement at the same site) surfaces, a potential advantage over the 
purely antiresorptive agents that inhibit bone formation at remodelling sites. 
A study of a human anti-TGFb antibody, fresolimumab, is underway in adults 
with OI in North America. Preclinical work suggests substantial restoration of 
bone mass in mouse models of OI using the mouse 1D11 anti-TGFb antibody.66 In 
addition, the use of 1D11 was associated with an improvement in lung tissue 
morphology, increasing alveolar number. None of the proposed studies include 
infants, but once safety and efficacy have been shown in the older age groups we ǲǳ
eventually neonates.  
As yet, no intervention has emerged that alters the material quality of bone; one 
potential approach to this issue would be the removal of mutant protein prior to 
its export from the cell, a process called autophagy. Autophagy enhancement 
could be used, but it is unclear as yet whether the degree of enhancement that 
can be achieved is sufficient to keep up with the production of mutant type I 
collagen molecules.67 Another approach would be to replace the mesenchymal 
stem cells (MSCs) that give rise to osteoblasts. Bone marrow transplantation was  ? ? ? ?ǯ68 but low levels of engraftment and lack of evidence of the 
production of normal type I collagen from transplanted cells, as well as safety 
concerns, led to suspension of the work. A recently proposed approach is that of 
using fetal MSCs administered both in utero and during infancy. The acid test will 
again be whether the investigators can demonstrate the production of type I 
collagen from the transplanted cells, or their daughter cells. 
 
Hypophosphatasia 
Hypophosphatasia (HPP) occurs when alkaline phosphatase (ALP) activity is 
insufficient to remove the mineralisation inhibitor pyrophosphate from 
mineralising bone surfaces. ALP also removes the phosphate from pyridoxal 5-
phosphate (PLP); pyridoxal then crosses the blood-brain barrier and is re-
phosphorylated.  PLP is a co-factor in multiple enzymatic processes, including 
those that result in the synthesis of some neurotransmitters.69 The phenotype of 
infants presenting around the time of birth is one of severe demineralisation, 
rachitic changes at the metaphyses with very gracile ribs, elevated serum 
calcium and phosphate, nephrocalcinosis, and in some cases pyridoxine-
dependent convulsions.70  
Prior to the advent of enzyme replacement therapy with asfotase alfa, over 90% 
of perinatally-presenting cases and 55% of cases presenting later in infancy died. 
The published results from the initial and subsequent cohorts70,71 of infants 
treated with asfotase alfa show an overall reduction in mortality to around 12%. 
Longer term follow-up suggests improvements in growth, motor and cognitive 
development in parallel with resolution of radiological changes.   
The improvement in bone mineralisation can take months to become apparent 
radiologically; continued respiratory support is usually required until ribs 
mineralise and become broader and are able to sustain normal respiratory 
activity. Pneumonia may be more common in HPP than would be expected and 
should certainly be considered in any infant with worsening respiratory 
function. Worsening radiological appearance is a red flag and should provoke 
consideration of whether drug is being absorbed.  It is unclear whether 
autoantibodies, present in at least 50%, affect efficacy.  The more severely 
affected infants, and those with radiological worsening of bone disease may 
require more than the licenced starting dose of 6mg/kg/week subcutanously.  
Hypercalcaemia requires institution of a low calcium diet initially; there can be a 
sudden change as increased bone mineralisation begins to place, so monitoring 
of serum calcium over the initial weeks is needed until the infant is established 
on asfotase alfa with a normal calcium intake. 
Convulsions may occur within the first week of life; pyridoxine (ideally 
pyridoxal) can help, and affected infants should usually be responsive to enzyme 
replacement therapy. Craniosynostosis occurs in at least 25% of cases; although 
unlikely to be present at birth, it can develop over the first 6-12 months of life 
and result in raised intracranial pressure; regular monitoring of head 
circumference and ophthalmological examination is required. 
 
Neonatal severe hyperparathyroidism 
Infants typically present within days of delivery with severe hypercalcemia, high 
circulating parathyroid hormone (PTH) and characteristic radiological changes 
including bone demineralisation, rachitic-shaped chest, fractures and periosteal 
elevation/double cortices.72 Affected infants have inactivating mutations of the 
calcium sensing receptor gene,73 so that PTH continues to be produced despite 
the hypercalcaemia. Rehydration is required urgently, and the administration of 
an intravenous bisphosphonate, usually pamidronate will both contribute to 
reducing serum calcium levels.  A small dose of pamidronate is usually given 
(0.5mg/kg over 4 hours), and may need repeating 24-48 hours later; 
administering larger doses can result in hypocalcaemia. Definitive treatment is 
surgical removal of the parathyroid glands; post-operatively hypocalcaemia will 
likely occur and may be problematic. 
 FGFR3 disorders 
Fibroblast growth factor receptor 3 (FGFR3)-dependent signalling regulates 
bone growth by affecting growth plate chondrocyte proliferation through STAT1 
and maturation through the MAPKs ERK1 and 274. 
Mutations in the FGFR3 gene that lead to it being functionally overactive result in 
a spectrum of conditions causing dwarfism from the lethal thanatophoric 
dysplasia to the milder hypochondroplasia.  The most common, achondroplasia, 
is often diagnosed at birth and is characterised by short long bones, shortening 
of the proximal skeleton and limited elbow extension.  Effects on the skull 
include macrocephaly, mid face hypoplasia, frontal bossing and a small foramen 
magnum.75   Thanatophoric dysplasia is a severe form of dwarfism and is usually 
lethal with infants stillborn or dying soon after birth due to respiratory failure.  
Affected infants have short limbs, a narrow thorax, macrocephaly and temporal 
lobe enlargement.  Patients with hypochondroplasia share a similar phenotype 
with achondroplasia but in a milder form and will often be diagnosed later in 
childhood75.   
 
Achondroplasia may be diagnosed antenatally on USS.  In neonates, a wrist 
radiograph shows delayed bone age; catch-up to chronological age occurs in 
adolescence.  MRI may demonstrate cervicomedullary compression at the 
foramen magnum; problems in infancy are unusual but do occasionally occur.  
Thanatophoric dysplasia has two types with a similar phenotype; type II has a 
tri-lobar skull with a clover-leaf appearance.   
 
Two mutations in the FGFR3 gene account for nearly all cases of achondroplasia 
with both mutations creating the same change to the FGFR3 protein, resulting in 
constitutive activation76.  80% of affected individuals have new mutations but 
when inherited it follows an autosomal dominant pattern with homozygous 
individuals stillborn or dying soon after birth. More than 10 mutations of the 
FGFR3 gene have been identified in cases of thanatophoric dysplasia; all result in 
ligand-independent activation of the FGFR3 protein77,78. 
 
Severe achondroplasia with developmental delay and acanthosis nigricans 
(SADDAN) is a very rare skeletal dysplasia accompanied by seizures, profound 
developmental delay and additional skin folds on the limbs.  In each of these 
lethal conditions individuals have only one affected gene due to the gain-of-
function nature of the affected protein.    Hypochondroplasia, as with 
achondroplasia, mostly arises from de novo mutations with 8 separate mutations 
identified to date.75  
 
Currently, treatment is supportive only, but identification of the activating 
mutations in the FGFR3 gene, and better understanding of the downstream 
consequences, have allowed the development of targeted treatments, with 
clinical trials now in progress.   
Vosoritideǡǲǳ-naturetic peptide based drug administered as a daily 
subcutaneous injection, has entered phase 3 clinical trials in children 
(https://clinicaltrials.gov/ct2/show/NCT02055157).  Vosoritide binds to a 
specific receptor (natriuretic peptide receptor 2) whose downstream signalling 
inhibits the downstream FGFR3 signalling pathway79.  Separately, a phase 1 trial 
commenced this year to assess TA-46, a soluble FGFR3 that sequesters FGFR3 
ligands and prevents the receptor from dimerising and signalling.  
 
Drugs used for no skeletal disorders are showing potential for their actions in 
bone.  Meclozine, an H1 antagonist used for motion sickness, promoted 
chondrocyte proliferation and differentiation for long bone growth in mice but 
with no effects on the axial skeleton80,81.  Its effects on bone have not been 
evaluated in humans.  PTH regulates bone metabolism and is used in adults to 
treat osteoporosis by promoting new bone formation.  Mouse pups with 
thanatophoric dysplasia born to mothers treated with subcutaneous PTH 
injections remained viable82.  Again, there are no human studies examining the 
effect on skeletal dysplasias and ǲǳ
use due to concerns regarding the possibility of causing osteosarcomas.   
Fibrodysplasias ossificans progressiva 
Fibrodysplasia ossificans progressiva (FOP) is an extremely rare autosomal 
dominant disorder characterised by the extra skeletal development of bone 
tissue through the ossification of skeletal muscle, ligaments and tendons.  The 
proximal, axial and cranial regions of the body are most commonly affected early 
which then progresses to more distal regions.  Trauma, surgery and viral 
illnesses trigger flare up that begin with soft tissue swellings and lead to mature 
bone formation.  A characteristic feature present at birth is a broad shortened 
deformed great toe.  Formal diagnosis relies on genetic testing which reveals an 
identical mutation in all affected patients for the ALK2/ACVR1 gene encoding the 
bone morphogenetic protein (BMP) type 1 receptor83.   Whilst it may be 
inherited, the majority of cases are new mutations.  The disease is characterised 
by flare-ups and there may be long periods of no disease activity.  Flare-ups are 
managed with high dose steroids and this has led to the suggestion that an 
underlying immunological component driving them84.   The retinoic acid 
receptor pathway (RAR) is known to be important in the process of bone 
formation.  Preclinical studies of RAR inhibition have shown reduction of injury-
induced bone formation and spontaneous bone formation in FOP mouse 
models85. Palovarotene, a retinoic acid receptor antagonist, is in a phase 3 
clinical trial of FOP to assess efficacy and safety 
(https://clinicaltrials.gov/ct2/show/NCT03312634).    
 
 
Future directions/summary 
As genomics progresses and testing using both targeted panels and whole  
exome/genome sequencing becomes routine, diagnosis will become easier.  
Although we are still some way away from the application of artificial 
intelligence to the analysis and recognition of skeletal dysplasia from plain 
radiographs, the opportunity there is clear.  New treatments are emerging for 
multiple bone diseases that will in time be applied from around the time of birth, 
and that have the potential to be both life saving and life transforming.  
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